Pharmos Corporation
99 Wood Avenue South
Suite 301
Iselin
New Jersey
08830
United States
Tel: 732-452-9556
Fax: 732-452-9557
Website: http://www.pharmoscorp.com/
Email: pharmos@compuserve.com
77 articles about Pharmos Corporation
-
Pharmos Corporation Reports Second Quarter 2012 Results
7/31/2012
-
Pharmos Corporation Announces Successful Completion of Proof-of-concept Clinical Trial of Levotofisopam for the Treatment of Gout
5/18/2012
-
Pharmos Corporation Reports First Quarter 2012 Results
4/16/2012
-
Pharmos Corporation Provides Update on Ongoing Clinical Trial of Levotofisopam for the Treatment of Gout
4/6/2012
-
Pharmos Corporation Reports 2011 Fourth Quarter and Full Year Results
2/21/2012
-
Pharmos Corporation Announces Dosing of First Patients in Clinical Trial of Levotofisopam for the Treatment of Gout
1/11/2012
-
Pharmos Corporation Reports 2011 Third Quarter Results
11/1/2011
-
Pharmos Corporation Reports 2011 Second Quarter Results
8/9/2011
-
Pharmos Corporation Reports First Quarter 2011 Results
4/29/2011
-
Pharmos Corporation Reports Fourth Quarter and Full Year 2010 Results
2/18/2011
-
Pharmos Corporation Reports 2010 Third Quarter Results
10/27/2010
-
Pharmos Corporation Reports 2010 Second Quarter Results
8/5/2010
-
Pharmos Corporation Reports First Quarter 2010 Results
5/13/2010
-
Pharmos Corporation Reports Fourth Quarter and Full Year 2009 Results
2/23/2010
-
Pharmos Corporation Announces Results of Phase 2b Irritable Bowel Syndrome Study
9/14/2009
-
Pharmos Corporation Reports 2009 Second Quarter Results
8/13/2009
-
Delisting of Securities of Pharmos Corporation From The NASDAQ Stock Market
6/23/2009
-
Pharmos Corporation Reports 2009 First Quarter Results
5/13/2009
-
Pharmos Corporation Completes Private Placement - Raises $1.8 Million
4/22/2009
-
Pharmos Corporation Issues Business Update on Dextofisopam Trial and Financing
4/3/2009